David Orren is an internationally-experienced business executive delivering business strategies for disruptive innovation companies. David has teamed with world-renowned neuropsychopharmacologist, Professor Dave Nutt, to develop Alcarelle, a novel biomimetic GABAergic compound designed to give adult drinkers what they want from alcohol, without the alcohol. The goal is to disrupt and revolutionise the adult social drinking market. David cofounded the business as a biochemical research engine developing it through to a business able to take Alcarelle through the US FDA GRAS Market Approval process. In parallel David and his team have built the drinks subsidiary Sentia Spirits, releasing the world's first science-based GABAergic functional alternative to alcohol. As a proof-of-concept botanical spirit, Sentia has taken the market by storm acquiring over 40,000 customers from inception.Alcarelle will go through the FDA regulatory process during 2023 to 2027, entering the US market as an ingredient sold to the Drinks Industry in 2028, then expanding into the EU during 2029, and Japan in 2030.